Biologicals dominate Europe’s best sellers

Home/Reports | Posted 27/06/2014 post-comment2 Post your comment

The landscape of blockbuster medicines in Europe has been changing over the last years from small molecule drugs to biologicals.

EU Flag V12K23

Biologicals now dominate the top 10 list of best-selling medicines in Europe, with eight of the top 10 best-selling drugs now being biologicals. This compares to only three biologicals that made the top 10 list back in 2008, see Table 1.

Table 1: Top 10 best-selling drugs in Europe 2008–2013

GW 1814G Table 1

Source: IMS Health, MIDAS, MAT June 2013

The patents on all of these blockbuster biologicals have already expired or expire by 2022 at the latest [1], making them targets for biosimilars developers.

There are also more than 200 new biologicals in the pipeline (phase II to be registered), all of which could also be future targets for biosimilars [2].

Related article
The global biologicals market

References
1. GaBI Online - Generics and Biosimilars Initiative. US$67 billion worth of biosimilar patents expiring before 2020 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 27]. Available from: www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020
2. GaBI Online - Generics and Biosimilars Initiative. Biotech pipeline and biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 27]. Available from: www.gabionline.net/Biosimilars/Research/Biotech-pipeline-and-biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (2)
Post your comment
Posted 05/08/2014 by Justyna K, GaBI Online Editorial Office
Response to 'Top 10 best-selling drugs in Europe 2008–2013'

Dear Mr Kashi, Thank you for your comment. We have also noticed this error and subsequently updated the article. Please continue with your valuable feedback. Kind regards, Justyna

Posted 29/06/2014 by Ramesh Kashi
Top 10 best-selling drugs in Europe 2008–2013

Lipitor (column 2012 / row 5) in Table 1 is not a biologic (high-lighted in yellow)

Related content
Brazilian market of biosimilars
Brazil flag V13C03
Home/Reports Posted 20/05/2022
China–EU market expansion for biosimilars
18794124_l
Home/Reports Posted 16/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010